Electrochemiluminescence Immunoassay
Electrochemiluminescence Immunoassay - Related Videos
10:12
A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
0 Views •
Cited by 16 •
2013
Measuring biomarkers in complex biological samples is increasingly guiding clinical decision-making. We describe a highly sensitive method to simultaneously measure cardiac myosin binding protein-C, creatine kinase MB, and cardiac troponin I in serum samples from subjects with myocardial infarction and healthy control subjects.
06:09
Detection of Human Islet Autoantibodies Using an Electrochemiluminescence Assay
0 Views •
2025
This video showcases the electrochemiluminescence detection of islet autoantibodies in human serum. The antibodies in the serum bridge the ruthenium-conjugated antigen to the biotinylated capture antigen, forming complexes that are detected by electrochemiluminescence measurements.
06:25
Electrochemiluminescence Assay for Quantification of Target Protein Levels in Brain Lysate
0 Views •
2025
In this video, we demonstrate the electrochemiluminescence immunoassay for the quantitation of target protein levels in different samples. This assay is based on the luminescence produced in the electrochemical reaction. The intensity of light emitted is proportional to the quantity of the target protein in the sample.
08:05
Multiplexed Fluorometric ImmunoAssay Testing Methodology and Troubleshooting
0 Views •
Cited by 19 •
2011
Using Luminex Corporation’s xMAP microsphere technology, we have developed the Multiplexed Fluorometric ImmunoAssay (MFIA) for serosurveillance of various laboratory animal species. The MFIA is a suspension microarray where antigen, tissue control or immunoglobulins are covalently linked to color-coded polystyrene microspheres. The MFIA testing method as well as various troubleshooting topics is addressed.
07:32
A Capillary Electrophoresis Immunoassay for Protein Biomarker Detection
0 Views •
2025
This video demonstrates a capillary electrophoresis immunoassay protocol for detecting a protein biomarker associated with amyotrophic lateral sclerosis (ALS) from human blood platelets. Confirmation of the presence of the ALS biomarker protein is achieved through size-based separation of the platelet proteins followed by chemiluminescent detection.
FAQs
The signal-generating complex depends on the target being recognized by both a capture antibody and a labeled detection antibody. This arrangement links the amount of bound target to the amount of electrochemiluminescent label associated with the assay complex. As a result, light intensity provides a quantitative readout of the target molecule rather than merely indicating whether binding occurred.
The electrode provides the controlled electrical stimulus needed to activate the electrochemiluminescent tag. When an applied potential stimulates that label, it produces light at the electrode. Measuring this emitted light converts the antibody-binding event into an instrumental signal, allowing the assay platform to quantify proteins and other biomarkers in a sample.
A broad dynamic range allows one assay format to measure targets across a relatively wide span of concentrations, while low background helps distinguish genuine analyte-associated signal from nonspecific light or baseline response. Together, these characteristics support sensitive quantitative analysis and make the method useful for comparing biomarker levels across clinical and research samples.
A typical workflow brings the sample target into contact with a capture antibody and a labeled detection antibody, forming the assay complex. The platform then applies an electrical potential to stimulate the label at an electrode and measures the resulting light. Signal intensity is interpreted in relation to analyte amount, producing a quantitative result.
The format can be adapted to measure antibodies, antigens, cytokines, and other infection-associated biomarkers. Its antibody-based recognition makes it suitable for analyzing immune molecules as well as targets linked to disease. This range supports both focused tests for a particular analyte and broader immune profiling using clinical or research samples.
In immunology and infection studies, ECLIA supports serology, immune profiling, disease diagnosis, and monitoring responses to infection or vaccination. Researchers can select assays for antibodies, antigens, cytokines, or other infection-associated biomarkers, then use their quantitative signals to characterize immune status or follow changes associated with disease and immune response.
Compatibility with automated platforms allows ECLIA measurements to be incorporated into standardized analytical workflows rather than performed only as isolated manual assays. Combined with sensitive detection, low background, and a broad dynamic range, this automation supports consistent analysis of clinical and research samples and facilitates testing across multiple protein or immune-related biomarkers.